Erin Weeda to Cost-Benefit Analysis
This is a "connection" page, showing publications Erin Weeda has written about Cost-Benefit Analysis.
Connection Strength
1.138
-
Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life. Int J Cardiol. 2018 Dec 15; 273:34-38.
Score: 0.540
-
Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Intern Emerg Med. 2017 Apr; 12(3):311-318.
Score: 0.472
-
Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. J Diabetes Complications. 2018 02; 32(2):210-215.
Score: 0.126